In human patients with AD, knockdown of MEF2C downregulates expression levels of the components of the NRF2-ARE pathway (Ren et al., 2022), implying that resilience networks may collaborate to synergistically alter disease progression. Here, MEF2C is linked to Alzheimer disease.